MRMD · Marimed Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.48M | - | $40.76M | $39.61M | $37.95M | - | $40.59M | $40.44M | $37.93M | - |
| Cost of Revenue | $24.20M | - | $24.40M | $23.58M | $22.82M | - | $23.81M | $23.53M | $21.46M | - |
| Gross Profit | $15.28M | - | $16.36M | $16.03M | $15.14M | - | $16.78M | $16.91M | $16.47M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $6.89M | - | $6.59M | $6.34M | $6.25M | - | $6.10M | $6.80M | $6.14M | - |
| Total Operating Expenses | $15.15M | - | $14.76M | $14.89M | $15.99M | - | $15.44M | $15.95M | $14.45M | - |
| D&A | $2.15M | - | $2.10M | $2.10M | $1.81M | - | $1.80M | $2.00M | $1.94M | - |
| Operating Income | $125.0K | - | $1.60M | $1.14M | ($851.0K) | - | $1.34M | $956.0K | $2.02M | - |
| Interest Expense | $1.98M | - | $1.82M | $1.76M | $1.63M | - | $2.48M | $2.64M | $1.63M | - |
| Income Tax | $2.65M | - | $2.76M | $691.0K | $2.83M | - | $655.0K | $866.0K | $1.69M | - |
| Net Income | ($3.79M) | - | ($2.95M) | ($1.27M) | ($5.45M) | - | ($1.01M) | ($1.65M) | ($1.30M) | - |
| EPS - Basic | ($0.01) | - | ($0.01) | $0.00 | ($0.01) | - | $0.00 | $0.00 | $0.00 | - |
| EPS - Diluted | ($0.01) | - | ($0.01) | $0.00 | ($0.01) | - | $0.00 | $0.00 | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.94M | $8.88M | $6.60M | $6.14M | $7.20M | $7.28M | $9.79M | $10.19M | $15.23M | $14.64M |
| Accounts Receivable | $9.44M | $9.11M | $7.96M | $7.69M | $9.18M | $8.74M | $7.32M | $7.74M | $6.49M | $7.20M |
| Inventory | $39.30M | $36.60M | $40.04M | $38.83M | $37.56M | $33.49M | $34.98M | $31.14M | $29.04M | $25.31M |
| Accounts Payable | $15.11M | $14.59M | $11.24M | $11.22M | $13.97M | $13.19M | $12.98M | $11.85M | $10.26M | $9.00M |
| Current Assets | $60.79M | $59.29M | $60.09M | $57.13M | $58.00M | $53.51M | $56.68M | $53.05M | $54.90M | $51.43M |
| Total Assets | $201.19M | $202.56M | $205.60M | $204.37M | $208.00M | $206.99M | $212.68M | $208.53M | $201.33M | $196.12M |
| Current Liabilities | $63.76M | $59.07M | $56.58M | $50.94M | $55.31M | $48.68M | $44.60M | $40.66M | $35.45M | $30.86M |
| Long-term Debt | $82.54M | $76.04M | $76.24M | $77.48M | $77.36M | $78.19M | $79.41M | $79.50M | $76.64M | - |
| Total Liabilities | $147.74M | $137.83M | $136.55M | $131.20M | $134.06M | $128.11M | $125.84M | $120.93M | $113.51M | $107.21M |
| Stockholders' Equity | $46.51M | $50.01M | $54.32M | $58.45M | $59.21M | $59.88M | $67.84M | $68.60M | $68.82M | $69.91M |
| Retained Earnings | ($131.72M) | ($127.93M) | ($123.30M) | ($118.84M) | ($117.57M) | ($112.12M) | ($103.92M) | ($102.90M) | ($101.25M) | ($99.95M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $949.0K | - | - | - | $1.29M | - | - | - | $3.21M | - |
| Investing Cash Flow | ($753.0K) | - | - | - | ($115.0K) | - | - | - | ($4.27M) | - |
| Financing Cash Flow | ($1.14M) | - | - | - | ($1.26M) | - | - | - | $1.65M | - |
| CapEx | $373.0K | - | - | - | $266.0K | - | - | - | $3.37M | - |
| Free Cash Flow | $576.0K | - | - | - | $1.03M | - | - | - | ($158.0K) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 38.7% | - | 40.1% | 40.5% | 39.9% | - | 41.3% | 41.8% | 43.4% | - |
| Operating margin | 0.3% | - | 3.9% | 2.9% | -2.2% | - | 3.3% | 2.4% | 5.3% | - |
| EBITDA margin | 5.8% | - | 9.1% | 8.2% | 2.5% | - | 7.7% | 7.3% | 10.4% | - |
| Net margin | -9.6% | - | -7.2% | -3.2% | -14.4% | - | -2.5% | -4.1% | -3.4% | - |
| Free cash flow margin | 1.5% | - | - | - | 2.7% | - | - | - | -0.4% | - |
| FCF / Net income | -0.15 | - | - | - | -0.19 | - | - | - | 0.12 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 17.4% | - | 16.2% | 16.0% | 16.5% | - | 15.0% | 16.8% | 16.2% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 431.1% | - |
| Return on assets | -1.9% | - | -1.4% | -0.6% | -2.6% | - | -0.5% | -0.8% | -0.6% | - |
| Return on equity | -8.1% | - | -5.4% | -2.2% | -9.2% | - | -1.5% | -2.4% | -1.9% | - |
| Return on invested capital | 0.1% | - | 1.0% | 0.7% | -0.5% | - | 0.7% | 0.5% | 0.7% | - |
| Liquidity | ||||||||||
| Current ratio | 0.95 | 1.00 | 1.06 | 1.12 | 1.05 | 1.10 | 1.27 | 1.30 | 1.55 | 1.67 |
| Quick ratio | 0.34 | 0.38 | 0.35 | 0.36 | 0.37 | 0.41 | 0.49 | 0.54 | 0.73 | 0.85 |
| Cash ratio | 0.12 | 0.15 | 0.12 | 0.12 | 0.13 | 0.15 | 0.22 | 0.25 | 0.43 | 0.47 |
| Leverage | ||||||||||
| Debt / Equity | 1.77 | 1.52 | 1.40 | 1.33 | 1.31 | 1.31 | 1.17 | 1.16 | 1.11 | - |
| Debt / Assets | 0.41 | 0.38 | 0.37 | 0.38 | 0.37 | 0.38 | 0.37 | 0.38 | 0.38 | - |
| Debt / EBITDA | 36.23 | - | 20.61 | 23.91 | 80.93 | - | 25.29 | 26.90 | 19.36 | - |
| Interest coverage | 0.1x | - | 0.9x | 0.6x | -0.5x | - | 0.5x | 0.4x | 1.2x | - |
| Equity multiplier | 4.33 | 4.05 | 3.78 | 3.50 | 3.51 | 3.46 | 3.13 | 3.04 | 2.93 | 2.81 |
| Liabilities / Assets | 0.73 | 0.68 | 0.66 | 0.64 | 0.64 | 0.62 | 0.59 | 0.58 | 0.56 | 0.55 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.20 | 0.19 | 0.18 | - | 0.19 | 0.19 | 0.19 | - |
| Inventory turnover | 0.62 | - | 0.61 | 0.61 | 0.61 | - | 0.68 | 0.76 | 0.74 | - |
| Days sales outstanding | 87d | - | 71d | 71d | 88d | - | 66d | 70d | 62d | - |
| Days inventory outstanding | 593d | - | 599d | 601d | 601d | - | 536d | 483d | 494d | - |
| Days payable outstanding | 228d | - | 168d | 174d | 223d | - | 199d | 184d | 174d | - |
| Cash conversion cycle | 452d | - | 502d | 498d | 466d | - | 403d | 369d | 382d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.6x | - | 1.1x | 0.5x | 0.6x | - | 1.0x | 1.0x | 1.4x | - |
| P / S | 0.7x | - | 1.4x | 0.7x | 0.9x | - | 1.6x | 1.7x | 2.6x | - |
| EV / EBITDA | 44.8x | - | 34.6x | 30.3x | 111.0x | - | 43.0x | 46.7x | 40.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 4.0% | - | 0.4% | -2.0% | 0.1% | - | 4.6% | 10.7% | 10.3% | - |
| Revenue CAGR (3y) | 4.7% | - | 7.1% | 6.3% | 6.7% | - | 6.9% | 7.5% | 15.5% | - |
| Revenue CAGR (5y) | 9.9% | - | 24.8% | 32.7% | 38.4% | - | 29.3% | 9.5% | 60.9% | - |
| Gross profit growth (YoY) | 0.9% | - | -2.5% | -5.2% | -8.1% | - | -0.4% | 3.3% | 7.0% | - |
| Operating income growth (YoY) | - | - | 19.3% | 19.4% | - | - | -59.3% | -73.0% | -60.6% | - |
| Net income growth (YoY) | 30.6% | - | -191.6% | 23.1% | -320.0% | - | 76.3% | -72.3% | -101.2% | - |
| EPS growth (YoY) | 0.0% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -43.9% | - | - | - | - | - | - | - | 97.9% | - |
| FCF CAGR (5y) | -33.6% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -21.4% | -16.5% | -19.9% | -14.8% | -14.0% | -14.4% | -15.1% | -15.2% | 5.4% | 22.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$159.83M totalProduct Sales$89.02M · 55.7%
Product Sales Wholesale$69.58M · 43.5%
Other$1.22M · 0.8%
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing MARIMED INC. against the 5 most active filers in the same SIC group.